Sign In
Buy TAK
$15.03
-0.150 (-0.99%)
At Close: Jun 03, 2026
Prometheus Biosciences Starts $125 Million IPO Plan
04:53pm, Thursday, 25'th Feb 2021
Prometheus Biosciences Starts $125 Million IPO Plan
BioLife Plasma Services Announces Expansion of Plasma Donation Centers Into California
11:00am, Wednesday, 24'th Feb 2021
MORENO VALLEY, Calif.--(BUSINESS WIRE)--BioLife Plasma Services announces expansion of plasma donation centers into California.
Takeda Doses First Participant In Novavax COVID-19 Vaccine Study In Japan
06:21am, Wednesday, 24'th Feb 2021
Takeda Pharmaceutical Co Ltd (NYSE: TAK) said that the first patient had been dosed with Novavax Inc's (NASDAQ: NVAX) COVID-19 vaccine candidate (dubbed as TAK-019) in a Japanese clinical trial
Takeda Provides Updates on Phase 1/2 Clinical Trials of Novavax' and Moderna's COVID-19 Vaccine Candidates in Japan
01:00am, Wednesday, 24'th Feb 2021
OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) announced today that the first subject was dosed in its Phase 1/2 immunogenicity and safety study of Novavax' C
ARKG: Precautionary Measures, But Transformational Objectives Remain Intact
09:23am, Monday, 22'nd Feb 2021
Cathie Wood and her team have shown investors that they have the capability to turn double-digit growth dreams into reality.
Are Investors Undervaluing Takeda Pharmaceutical Co. (TAK) Right Now?
12:52pm, Friday, 19'th Feb 2021
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
Takeda Receives Prestigious EURORDIS 2021 Black Pearl Award for Patient Engagement
06:01am, Thursday, 18'th Feb 2021
ZURICH--(BUSINESS WIRE)-- #EURORDISAwards2021--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) Takeda has been announced the winner of the EURORDIS 2021 Award for Patient Enga
OSAKA, Japan--(BUSINESS WIRE)--Takeda's Maribavir Phase 3 Clinical Trial Met Primary Endpoint
Takeda Files Japan Marketing Application For Darvadstrocel In Crohn's Disease
06:06am, Wednesday, 10'th Feb 2021
Takeda Pharmaceutical Co Ltd (NYSE: TAK) has applied to the Japanese regulatory authority seeking approval for Darvadstrocel (Cx601) to treat complex perianal fistulas in adult patients with non-a
OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it has submitted an application to the Japanese Ministry of Health, Labour
Takeda Pharmaceutical Co Ltd (TAK) CEO Christophe Weber on Q3 2021 Results - Earnings Call Transcript
12:55am, Friday, 05'th Feb 2021
Takeda Pharmaceutical Co Ltd (TAK) CEO Christophe Weber on Q3 2021 Results - Earnings Call Transcript
OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TOKYO:4502/NYSE:TAK) (“Takeda”) today announced financial results for the third quarter of fiscal year 2020 (period ended Dece
OSAKA, Japan--(BUSINESS WIRE)--Data at EAHAD 2021 Highlight Value of Takeda's Leading Hematology Portfolio in Clinical Settings and Commitment to Patient-Focused Advancements
Takeda Completes Sale of TachoSil® to Corza Health
02:00am, Monday, 01'st Feb 2021
OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it has completed the previously announced sale of TachoSil® Fibrin Sealant
Takeda Completes Sale of Select OTC and Non-Core Assets to Hypera Pharma
04:00pm, Friday, 29'th Jan 2021
OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced the completion of its previously-announced sale of a portfolio of select product
